Table 2.
SMR of SPBC in cancer survivors by site and treatment of FPC
| Site of FPC | SMR of SPBC (95% CI) | Treatment of first primary cancer | |||
|---|---|---|---|---|---|
|
| |||||
| No radiation or chemotherapy | Radiation | Chemotherapy | Radiation and chemotherapy | ||
| Thyroid | 0.52* (0.44-0.62) | 0.54* (0.43-0.67) | 0.48* (0.40-0.70) | / | / |
| Melanoma of Skin | 0.59* (0.51-0.68) | 0.58* (0.51-0.67) | 1.04 (0.28-4.03) | / | / |
| Uteri | 0.66* (0.60-0.73) | 0.62* (0.56-0.71) | 0.98 (0.73-1.26) | 1.27 (0.86-1.74) | 0.76 (0.50-1.46) |
| Urinary | 0.51* (0.44-0.58) | 0.50* (0.46-0.59) | / | 0.50* (0.24-0.78) | / |
| Colon/Rectum/Anus | 0.55* (0.51-0.60) | 0.56* (0.51-0.62) | 0.59 (0.28-1.43) | 0.56* (0.45-0.67) | 0.49* (0.32-0.64) |
| Ovarian | 0.65* (0.53-0.79) | 0.61* (0.39-0.80) | / | 0.66* (0.55-0.86) | / |
| Lymphoma/Leukemia | 0.51* (0.46-0.57) | 0.49* (0.37-0.60) | 0.39* (0.16-0.58) | 0.58* (0.44-0.67) | 0.44* (0.32-0.76) |
| Oral/Pharynx | 0.77* (0.61-0.95) | 0.51* (0.35-0.72) | 1.08 (0.72-1.50) | 2.57 (0.28-8.42) | 1.11 (0.64-1.58) |
| Lung/Bronchus | 1.71* (1.58-1.85) | 1.05 (0.91-1.71) | 2.25* (1.67-2.59) | 2.42* (1.96-2.78) | 3.01* (2.49-3.29) |
*
indicates that SMR is statistically significant.
SPBC: second primary breast cancer; SMR: Standardized mortality ratios; FPC: first primary breast cancer.